Phase 3 Randomized, Double-blind, Placebo controlled Study to Evaluatethe Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity inParticipants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fractionand Obesity (MARITIME-HF)]

• Protocol code: 20230227
• EudraCT code: No aplica
• Research group: Cardiovascular Diseases
• Service: Cardiology
• Principal investigator:  Soriano Colomé, Toni
• Pathology: Malalties del sistema circulatori
• Phase: Fase III